If you are taking a GLP-1 medication such as semaglutide (Wegovy or Ozempic) or tirzepatide (Zepbound or Mounjaro), you have probably watched the scale drop faster than you thought possible. That progress is exciting, and yet it often arrives with a quiet worry sitting right behind it. You start to wonder whether the weight leaving your body is fat, or whether you are losing hard-won muscle along with it. Our guide to weight loss and testosterone on GLP-1 therapy covers the hormonal side of that same question.
That worry is reasonable. When you lose weight quickly, your body does shed both fat and lean tissue, so the question is fair rather than paranoid. The good news is that we now have detailed body-composition data from large trials and recent reviews, and those numbers tell a more reassuring story than the scale alone ever could. A GLP-1 muscle loss DEXA scan is the single best tool for separating fat from muscle, so in this blog post we will discuss what the research really shows about GLP-1 and muscle, why that scan reads “lean mass loss” even when your muscle is intact, and what you can do to protect your strength while you slim down.
Is Losing Weight the Same as Losing Fat?
It is a common misconception that every pound lost is a pound of progress. Your real goal is not simply to be smaller, it is to be metabolically healthier, which means losing as much fat as possible while holding on to your skeletal muscle.
Muscle is your metabolic currency. It helps regulate your blood sugar, it supports your joints, and it keeps your resting metabolism ticking over. Because GLP-1 medications reduce appetite so powerfully, they can produce a steep calorie deficit, and that is exactly why your body composition matters far more than the single number under your feet. The same blood-sugar link runs the other way too, which we cover in our piece on insulin resistance and low testosterone.
Rest assured, a falling scale and a healthier body are not in conflict here. They simply are not the same measurement.
What Does the Research Say About Lean Mass and Fat Mass?
The trials behind these medications used dual-energy X-ray absorptiometry, the DEXA scan, to measure precisely what people were losing. According to PubMed, the STEP 1 trial of once-weekly semaglutide produced a mean weight loss of about 15% of body weight over 68 weeks[1]. The SURMOUNT-1 trial of tirzepatide pushed average weight loss to roughly 21% at the highest dose[2]. The DEXA-based breakdown of how much of that loss was fat and how much was lean tissue comes from pooled body-composition analyses of these same trials[3].
So how much of that loss was lean tissue rather than fat? A 2026 systematic review and meta-analysis of 20 randomised trials covering 15,782 participants gives the cleanest answer we have. Lean mass made up 35.2% of total weight lost with semaglutide, 25.4% with tirzepatide, and 26.8% with liraglutide[3]. Those figures might sound high until you see the comparison. Lifestyle-only weight loss in the same analysis lost a strikingly similar proportion as lean mass, around 26.2%, which tells you these drugs are not singling out your muscle. Muscle loss is a natural part of any meaningful weight loss, not a special hazard of the medication.
What is more, that same review found the most protective approach of all. People who combined lifestyle changes with resistance training lost only about 17.5% of their weight as lean mass, the most favourable profile in the entire dataset.
However, the picture deserves honesty as well as reassurance. A separate 2026 systematic review in Annals of Internal Medicine found that across incretin studies, the median share of weight lost from muscle-related tissue was 34.9%, and roughly two thirds of those studies exceeded the standard 25% benchmark for expected lean-mass loss[4]. In plain terms, some people on these medications do lose more muscle than they should if the weight loss is left unmanaged, which is precisely why a generic crash-diet mindset is the wrong way to use a powerful drug.
What Is a DEXA Scan Actually Measuring?
This is where the DEXA scan earns its place in your plan. A bathroom scale cannot tell five pounds of fat from five pounds of water or muscle, but a DEXA scan separates your body into fat mass, bone mineral, and lean tissue, so you can see which compartment is actually changing.
Here is the nuance that even many articles get wrong. The “lean tissue” a DEXA reports is not pure skeletal muscle. It also includes water, glycogen (the stored energy packed inside your muscles), and the weight of your organs. When you first start a GLP-1, you tend to drop a lot of water and glycogen, and the scan records that as “lean mass loss” even though you have not lost a single muscle fibre. Truly tracking muscle (rather than total lean mass) is one reason researchers are now exploring muscle-preserving add-on therapies alongside GLP-1 drugs, an area a careful clinician watches closely[5].
A single early scan, then, can look alarming for reasons that have nothing to do with your strength.
How Can You Protect Your Muscle While Losing Weight?
You do not have to accept muscle loss as an unavoidable side effect, because you have real influence over it. Two habits do most of the work, and they reinforce each other.
The most important signal you can send your body is resistance training. By lifting weights or doing bodyweight exercises a few times a week, you effectively tell your body that your muscle is needed, which makes it far more likely to pull energy from fat stores instead of muscle. Protein does the second half of the job. A 2025 international consensus on optimising GLP-1 therapy recommends a protein intake above 1.2 g per kilogram of body weight per day, spread evenly across meals and paired with both aerobic activity and structured resistance training, to preserve lean mass[6]. Your own clinician or dietitian can set a target that fits your kidneys, your kilograms, and your goals, so treat that figure as a starting point for a conversation rather than a prescription.
Why Function Matters More Than the Printout
What matters in the end is how you move and feel, not a line on a report. This is where some of the most encouraging recent data comes in. In the SEMALEAN study, which followed patients on semaglutide with DEXA scans, lean mass dipped early and then stabilised, while handgrip strength actually improved by about 4.5 kg by the twelve-month mark[7]. Even more telling, the share of patients with sarcopenic obesity (low muscle combined with excess fat) fell from 49% at the start to 33% by month twelve.
In other words, people were not just lighter. They were functionally stronger relative to their size, because they were carrying far less fat over a muscle base that held up. Broader reviews echo this, reporting that GLP-1 medications reduce fat mass more than lean mass and that measured strength and physical function tend to be preserved rather than lost[5]. The lesson is to read the right number rather than the obvious one, much as we argue in our explainer on free versus total testosterone.
Use the DEXA scan as your map. Use your protein and your training as your protection.
Conclusion
The number on your scale is honest, but it is incomplete, because it cannot tell muscle from fat from water. The body-composition evidence is reassuring on the whole. GLP-1 medications take more fat than muscle, the proportion of lean mass lost is broadly similar to what happens with any significant weight loss, and measured strength often holds or improves. However, the same evidence is clear that the people who protect their muscle best are the ones who train and eat for it, rather than relying on the drug alone.
No doubt the smartest move you can make is to bring this information to your own doctor, who can read your DEXA scan in the context of your history and help you build a plan that leaves you stronger, leaner, and more capable than when you started.
References
- [1] Wilding JPH et al., N Engl J Med. 2021, PMID 33567185
- [2] Jastreboff AM et al., N Engl J Med. 2022, PMID 35658024
- [3] Eisa N et al., Diabetes Obes Metab. 2026, PMID 41877354
- [4] Batsis JA et al., Ann Intern Med. 2026, PMID 41996180
- [5] De Girolamo et al., Eur J Clin Invest. 2025, PMID 41328795
- [6] Noronha JC et al., Obes Pillars. 2025, PMID 41322078
- [7] Alissou et al., Diabetes Obes Metab. 2025, PMID 41068996
Medically reviewed by Ahmed Zayed, MBBCh, a clinician with 12 years of practice. This article is for education and does not replace a consultation with your own doctor.
